B7-33: adverse events and evidence limits
B7-33 is a single-chain relaxin analogue. Hossain and colleagues tested prostate-tumour effects in mice: six animals in each of two B7-33 groups, receiving eight-day subcutaneous pump infusions. The authors found no exacerbation of tumour growth versus control. [1]
That experiment measured tumour size in one model. It establishes neither cancer safety nor human adverse-reaction frequencies for B7-33; findings about full-length relaxin cannot automatically be transferred to this analogue. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Exacerbation of prostate tumour growth | Mice, six animals in each of two B7-33 groups, eight-day subcutaneous pump infusion | Not found versus control; the experiment does not establish human adverse-reaction frequencies | [1] |
References
- Hossain MA, Kocan M, Yao ST, Royce SG, Nair VB, Siwek C, Patil NA, Harrison IP, Rosengren KJ, Selemidis S, Summers RJ, Wade JD, Bathgate RAD, Samuel CS. (2016). A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1 https://doi.org/10.1039/C5SC04754D.